GZ 389988

Drug Profile

GZ 389988

Alternative Names: GZ 389988A; GZ389988

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi; Sanofi Genzyme
  • Class Antirheumatics; Small molecules
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Osteoarthritis

Most Recent Events

  • 01 Apr 2016 Sanofi completes a phase I/II trial in Osteoarthritis (In adults, In the elderly) in Germany (Intra-articular) (EudraCT2014-004805-34; NCT02424942)
  • 02 Apr 2015 Phase-I/II clinical trials in Osteoarthritis (In adults, In the elderly) in Germany (Intra-articular) (EudraCT2014-004805-34; NCT02424942)
  • 28 Mar 2015 Pharmacodynamics data from preclinical studies in Osteoarthritis released by Genzyme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top